Therefore, DPP-IV enzyme inhibition and the development of the glucagon-like peptide-1 receptor (GLP-1R) agonists, resistant to enzymatic degradation, are important strategies for treating T2DM [56]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.